Jörn F Ziegler, Chotima Böttcher, Marilena Letizia, Cansu Yerinde, Hao Wu, Inka Freise, Yasmina Rodriguez-Sillke, Ani K Stoyanova, Martin E Kreis, Patrick Asbach, Desiree Kunkel, Josef Priller, Ioannis Anagnostopoulos, Anja A Kühl, Konstanze Miehle, Michael Stumvoll, Florian Tran, Broder Fredrich, Michael Forster, Andre Franke, Christian Bojarski, Rainer Glauben, Britt-Sabina Löscher, Britta Siegmund, Carl Weidinger
Leptin has been shown to modulate intestinal inflammation in mice. However, clinical evidence regarding its immune-stimulatory potential in human Crohn's disease remains sparse. We here describe a patient with the unique combination of acquired generalized lipodystrophy and Crohn's disease (AGLCD) featuring a lack of adipose tissue, leptin deficiency and intestinal inflammation. Using mass and flow cytometry, immunohistochemistry and functional metabolic analyses, the AGLCD patient was compared to healthy individuals and Crohn's disease patients regarding immune cell composition, function and metabolism and the effects of recombinant N-methionylleptin (rLeptin) were evaluated...
December 10, 2019: Nature Communications